These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

87 related items for PubMed ID: 7580173

  • 1. The effects of electroconvulsive shock on dopamine-1 and dopamine-2 receptor ligand binding activity in MPTP-treated mice.
    Sershen H, Wolinsky T, Douyon R, Hashim A, Wiener HL, Lajtha A, Coons EE, Serby M.
    J Neuropsychiatry Clin Neurosci; 1991; 3(1):58-63. PubMed ID: 7580173
    [Abstract] [Full Text] [Related]

  • 2. Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism.
    Graham WC, Sambrook MA, Crossman AR.
    Brain Res; 1993 Feb 05; 602(2):290-303. PubMed ID: 8095431
    [Abstract] [Full Text] [Related]

  • 3. Effect of adding the D-1 agonist CY 208-243 to chronic bromocriptine treatment of MPTP-monkeys: regional changes of brain dopamine receptors.
    Gagnon C, Gomez-Mancilla B, Markstein R, Bédard PJ, Di Paolo T.
    Prog Neuropsychopharmacol Biol Psychiatry; 1995 Jul 05; 19(4):667-76. PubMed ID: 8588064
    [Abstract] [Full Text] [Related]

  • 4. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
    Gnanalingham KK, Smith LA, Hunter AJ, Jenner P, Marsden CD.
    Synapse; 1993 Jun 05; 14(2):184-94. PubMed ID: 8332947
    [Abstract] [Full Text] [Related]

  • 5. Mitochondrial toxins in models of neurodegenerative diseases. II: Elevated zif268 transcription and independent temporal regulation of striatal D1 and D2 receptor mRNAs and D1 and D2 receptor-binding sites in C57BL/6 mice during MPTP treatment.
    Smith TS, Trimmer PA, Khan SM, Tinklepaugh DL, Bennett JP.
    Brain Res; 1997 Aug 15; 765(2):189-97. PubMed ID: 9313891
    [Abstract] [Full Text] [Related]

  • 6. Alterations in dopamine uptake sites and D1 and D2 receptors in cats symptomatic for and recovered from experimental parkinsonism.
    Frohna PA, Rothblat DS, Joyce JN, Schneider JS.
    Synapse; 1995 Jan 15; 19(1):46-55. PubMed ID: 7709343
    [Abstract] [Full Text] [Related]

  • 7. Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA receptors in the striatopallidal complex.
    Calon F, Goulet M, Blanchet PJ, Martel JC, Piercey MF, Bédard PJ, Di Paolo T.
    Brain Res; 1995 May 22; 680(1-2):43-52. PubMed ID: 7663983
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic effects of dopamine D1/D2 receptor agonists on detrusor hyperreflexia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys.
    Yoshimura N, Mizuta E, Yoshida O, Kuno S.
    J Pharmacol Exp Ther; 1998 Jul 22; 286(1):228-33. PubMed ID: 9655864
    [Abstract] [Full Text] [Related]

  • 9. Dopamine D1 and D2 receptors visualized in MPTP treated C57 mice by in vitro autoradiography: lack of evidence of receptor modifications in parkinsonian mice.
    Camps M, Ambrosio S, Ballarin M, Reiriz J, Blesa R, Mahy N.
    Pharmacol Toxicol; 1989 Sep 22; 65(3):169-74. PubMed ID: 2682595
    [Abstract] [Full Text] [Related]

  • 10. Changes in brain dopamine receptors in MPTP parkinsonian monkeys following L-dopa treatment.
    Alexander GM, Schwartzman RJ, Grothusen JR, Brainard L, Gordon SW.
    Brain Res; 1993 Oct 22; 625(2):276-82. PubMed ID: 8275309
    [Abstract] [Full Text] [Related]

  • 11. Chronic CY 208-243 treatment of MPTP-monkeys causes regional changes of dopamine and GABAA receptors.
    Gagnon C, Gomez-Mancilla B, Bédard PJ, Di Paolo T.
    Neurosci Lett; 1993 Nov 26; 163(1):31-5. PubMed ID: 7905197
    [Abstract] [Full Text] [Related]

  • 12. The effects of D1 and D2 dopamine receptor agonist and antagonist on parkinsonism in chronic MPTP-treated monkeys.
    Nomoto M, Fukuda T.
    Adv Neurol; 1993 Nov 26; 60():119-22. PubMed ID: 8093574
    [No Abstract] [Full Text] [Related]

  • 13. Functional interaction between dopamine D1 and D2 receptors in 'MPTP' monkeys.
    Luquin MR, Guillén J, Martínez-Vila E, Laguna J, Martínez-Lage JM.
    Eur J Pharmacol; 1994 Mar 03; 253(3):215-24. PubMed ID: 7911084
    [Abstract] [Full Text] [Related]

  • 14. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
    Rioux L, Frohna PA, Joyce JN, Schneider JS.
    Mov Disord; 1997 Mar 03; 12(2):148-58. PubMed ID: 9087972
    [Abstract] [Full Text] [Related]

  • 15. Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse.
    Araki T, Mikami T, Tanji H, Matsubara M, Imai Y, Mizugaki M, Itoyama Y.
    Eur J Pharm Sci; 2001 Jan 03; 12(3):231-8. PubMed ID: 11113642
    [Abstract] [Full Text] [Related]

  • 16. Differential vulnerability of dopamine receptors in the mouse brain treated with MPTP.
    Tanji H, Araki T, Nagasawa H, Itoyama Y.
    Brain Res; 1999 Apr 10; 824(2):224-31. PubMed ID: 10196452
    [Abstract] [Full Text] [Related]

  • 17. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
    LaHoste GJ, Marshall JF.
    Synapse; 1992 Sep 10; 12(1):14-26. PubMed ID: 1357762
    [Abstract] [Full Text] [Related]

  • 18. Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine.
    Morissette M, Goulet M, Calon F, Falardeau P, Blanchet PJ, Bédard PJ, Di Paolo T.
    Mol Pharmacol; 1996 Nov 10; 50(5):1073-9. PubMed ID: 8913337
    [Abstract] [Full Text] [Related]

  • 19. Effects of GM1 ganglioside treatment on pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian monkeys.
    Pope-Coleman A, Tinker JP, Schneider JS.
    Synapse; 2000 May 10; 36(2):120-8. PubMed ID: 10767059
    [Abstract] [Full Text] [Related]

  • 20. Dopamine D1 receptor and dopamine D2 receptor binding activity changes during chronic administration of nicotine in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice.
    Wiener HL, Lajtha A, Sershen H.
    Neuropharmacology; 1989 May 10; 28(5):535-7. PubMed ID: 2657481
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.